PubMed Health⌕ Search

PubMed · 14601017

Measuring explained variation in linear mixed effects models.

Abstract

We generalize the well-known R(2) measure for linear regression to linear mixed effects models. Our work was motivated by a cluster-randomized study conducted by the Eastern Cooperative Oncology Group, to compare two different versions of informed consent document. We quantify the variation in the response that is explained by the covariates under the linear mixed model, and study three types of measures to estimate such quantities. The first type of measures make direct use of the estimated variances; the second type of measures use residual sums of squares in analogy to the linear regression; the third type of measures are based on the Kullback-Leibler information gain. All the measures can be easily obtained from software programs that fit linear mixed models. We study the performance of the measures through Monte Carlo simulations, and illustrate the usefulness of the measures on data sets.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ronghui Xu. 2003-11-30. Measuring explained variation in linear mixed effects models.. https://doi.org/10.1002/sim.1572

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗